Clinical Trial Payment Vendors in 2026: What to Ask Before You Sign
Clinical trial payment vendors can ace the demo and still leave you with the wrong payment infrastructure.
One platform automates investigator payments but gives participants limited ways to access their money. Another makes participant reimbursement painless but has no answer for a retroactive site-budget amendment. A third enters only after a payment is approved, moving funds across countries, currencies, and payment methods.
All three land on the same procurement shortlist.
Before you compare features, pricing, or global coverage, establish which payment job each vendor is built to do and where another provider takes over. These nine questions expose those gaps before they become part of a multi-study contract.
Key Takeaways
- Separate site payments, participant payments, and fund delivery before shortlisting, so every demo maps to the job you are buying.
- Verify country, currency, and local payout coverage protocol by protocol instead of accepting a headline number.
- Trace one full payment cycle in the demo, from protocol event to reconciliation, to find where manual work remains.
- Price total cost per study and per payment, including card issuance, FX spread, and change orders.
- Settle exit terms, data ownership, and open participant balances during negotiation, not at renewal.
What Are You Actually Paying For?
This is where vendor comparisons go sideways. Buyers describe the requirement as “clinical trial payments” and receive demos built for a different job entirely. The phrase covers three, and vendors rarely do all three well.
Investigator Site Payments
Site payments follow the clinical trial agreement, negotiated per site and calculated from study data. A platform must handle eight distinct types:
- Visit-based payments triggered by completed procedures
- Milestone payments tied to enrollment or database lock
- Startup fees paid before any patient is screened
- Screen failures, frequently negotiated at a different rate
- Pass-through costs billed back to the sponsor
- Site-generated invoices
- Holdbacks retained until study closeout
- Contract amendments that change rates mid-study
The last four can create substantial administrative work. The Society for Clinical Research Sites identifies holdbacks and infrequent payment as pressures its site payment initiative is working to address.
Participant Payments and Reimbursements
Clinical trial participant payments must comply with the protocol, the informed consent document, and the IRB. The category covers visit stipends, travel reimbursement, mileage, meals, lodging, and general expense reimbursement with receipt capture.
Compensation and reimbursement carry different tax treatment, which matters more in 2026 than it did previously. IQVIA reports that roughly 80% of participant payments are still managed directly by trial sites, through manual processes.
Payout and Disbursement Infrastructure
Once a stipend, reimbursement, or site payment is approved, someone still has to deliver the funds. Payout providers move that money through bank transfers, cards, wallets, or local methods across the required countries and currencies.
Deciding what a person is owed and delivering it to them are separate jobs. A platform can calculate a milestone payment perfectly and still fail to land the funds in an Indonesian account. Some vendors do both. Many partner for the second, which is why a demo that looks complete can hide a third party you haven’t evaluated.
Before comparing vendors, decide which of the three jobs you are solving. A platform built for investigator payments may offer sophisticated amendment logic while providing fewer participant payout options. A participant-payment specialist may offer greater choice across cards, bank transfers, and wallets, while having little to say about retroactive amendments across 40 sites.
The 2026 Clinical Trial Payment Vendor Landscape
Treat the list below as a market map, not a ranking. Requirements differ enough between sponsors that no universal “best” vendor exists.
| Vendor / Platform | Primary emphasis | Differentiator to investigate |
| Greenphire (Suvoda) | Site and participant payments | Dedicated clinical payments heritage |
| IQVIA CTFS | Site, participant, and financial lifecycle | Broader trial financial suite |
| Medidata Site Payments | Site payments | EDC-driven payment automation |
| Sitero Mentor | Site and participant payments | CTMS and EDC connected workflows |
| Mednet | Site payments | Native eClinical ecosystem |
| Dash Solutions | Participant payments | Digital and physical payment cards |
| RealTime | Participant and site workflows | Research site ecosystem |
| Scout Clinical | Participant reimbursement and support | Concierge and travel services |
| Advarra | Participant and research workflows | Broader research technology ecosystem |
| TruCentive | Participant payments | Flexible payment delivery |
| PayQuicker | Participant payout and disbursement infrastructure | Global reach and multi-method payout delivery |
One correction for 2026: Greenphire is no longer independent. Suvoda and Greenphire completed their merger on April 24, 2025, and its products now sit inside Suvoda’s portfolio. Diligence documents describing it as standalone are outdated.
9 Questions to Ask Clinical Trial Payment Vendors Before You Sign
Each question is written to produce a demonstration, not an assurance.
1. Which Countries and Currencies Do You Actually Support?
Request the country list, currency list, local payout methods per country, FX handling and rate source, cross-border restrictions, and country-specific payment limits.
Vendors count headline numbers differently. IQVIA states its participant payment solution reaches 180+ countries. Medidata describes its site payment capability as paying in nearly every country and currency. PayQuicker is available in 210+ countries and territories. All three claims are defensible, and none confirms your Brazilian sites can receive a Pix transfer.
Country count is the wrong unit. Verify the currencies and payout methods each market requires.
2. How Automated Is “Automated”?
Ask the vendor to walk through one payment from protocol events through approval, calculation, invoice, payment, and reconciliation. Then count the manual steps. Six commonly survive: spreadsheet imports, visit validation, calculation checks, invoice approval, reconciliation, and answering payment-status questions.
An April 2026 comparison of clinical trial payment software notes that most solutions supplement existing financial processes rather than replace them. Hybrid models pairing system-generated invoices with manual checks remain common.
3. What Systems Does the Platform Integrate With?
List your stack first: EDC, CTMS, eCOA and ePRO, ERP, accounting, scheduling, and identity or KYC systems.
For each connection, ask one follow-up. Is this a native integration, a prebuilt connector, an API integration, a file transfer, or a manual upload? Those five answers carry very different implementation costs. Medidata states its product triggers calculations automatically as work is completed in any EDC. Confirm what “any EDC” requires for your system.
4. How Does the Vendor Handle Contract Amendments?
Trial budgets change constantly, and amendment handling is where site payment platforms differ.
Ask what happens when visit amounts change, procedures are added, amendments apply retroactively, or milestones move. Then ask whether the system recalculates prior payments automatically, or generates a reconciliation task for someone to work through. Most vendor pages advertise automation and say little about amendments.
5. How Quickly Do Sites and Participants Actually Get Paid?
“Fast” is not a measurement. Ask for the typical payment cycle, frequency options, approval-to-disbursement time, participant reimbursement turnaround, and exception handling time. Ask how each changes internationally.
The Society for Clinical Research Sites advocates monthly site payments because predictable frequency gives sites financial stability. For participants, slow reimbursement pushes the cost of participation onto the person least able to carry it.
6. What Payment Methods Can Participants Choose?
The available set generally includes prepaid cards, virtual cards, direct bank payment, ACH, digital wallets, checks, gift cards, and local country methods.
Ask whether the vendor forces every participant onto one mechanism. Then ask about card fees, ATM fees, lost card replacement, expiration and unspent balances, international acceptance, and accessibility for unbanked participants. A participant who cannot use the card you issued has effectively not been paid.
7. How Does the Platform Handle Tax and Regulatory Requirements?
Ask about tax reporting, withholding, VAT, participant thresholds, audit trails, and data residency.
This matters more in 2026. IRS Publication 1099 states that for tax years beginning after 2025, the minimum threshold for reporting certain payments on information returns increased to $2,000, up from $600. That changes when a Form 1099 is issued. It does not change whether compensation is taxable, and sponsors should not read the higher threshold as an exemption.
Institutions may also apply their own policies around participant documentation and reimbursement. The NIH IRB Office takes the position that documented out-of-pocket reimbursement is not taxable and does not count toward the threshold. Johns Hopkins applies its own rule requiring SSN or ITIN collection at $200 or more per participant per year, which is institutional policy rather than a federal requirement.
Ask each vendor how its platform accommodates sponsor and site policies above the federal minimum. Then confirm every tax position with your own tax, compliance, and legal teams.
8. Who Handles Payment Exceptions and Support?
Exceptions are the real workload. Ask who owns a failed card, a lost card replacement, a missing payment, a bank return error, and a reconciliation question.
Then ask about international support hours, languages, and response-time SLAs written into the contract. Ask whether support comes from the vendor or the card issuer.
9. What Does the Total Contract Actually Cost?
Request pricing for every line item: implementation, study setup, platform license, per-site and per-participant fees, transaction fees, card issuance and replacement, FX spread, integration, support, change requests, custom reporting, closeout, and minimum commitments.
FX spread deserves separate attention. A quoted transaction fee can look small beside an undisclosed currency margin applied to every international payment. Compare total cost per study and per payment.
Then ask the vendor to demonstrate, not describe. Have them create a study and site, enter a payment schedule, process a retroactive budget amendment, trigger a participant reimbursement and an investigator milestone payment, show a failed transaction and resolve it, then generate a reconciliation report with the full audit trail. A vendor who cannot demonstrate your exception scenarios has only shown you the happy path.
What Sites and Participants Actually Experience
IQVIA’s literature identifies payment delays, limited options, and reimbursement complexity as recurring participant complaints. Each is a design choice, not an unavoidable condition.
Reimbursement speed. A participant who fronts $80 in travel costs and waits five weeks has taken out an unplanned loan for the study. Ask for the median reimbursement time, not the target.
Payment choice and transparency. One payment method is convenient for the sponsor but exclusionary for anyone it doesn’t serve. Participants should also see what was paid and what is pending, or the coordinator becomes the payment help desk.
Portal visibility. Demo the sponsor, CRO, site, and participant views separately. A coordinator should answer four questions without emailing anyone: what was paid, against which visit, when, and what is outstanding. IQVIA and Medidata both position real-time visibility prominently, so treat it as a baseline.
Coordinator workload. Sites run on thin margins, and payment timing affects staffing. New portals and reconciliation steps can raise site workload while lowering sponsor workload. The best sponsor-side workflow is the wrong solution when it moves work onto sites.
Clinical Trial Payment Vendor Red Flags
- “Global” coverage claimed without a country-by-country list
- “Automated” workflows that still depend on spreadsheet imports
- One payment method offered to all participants
- FX pricing described as “competitive” rather than quoted
- Participant reimbursement times measured in weeks without a documented reason or SLA
- No documented exception handling workflow
- Contract amendments requiring vendor services to process
- Unclear ownership of unspent card balances
- Pricing quoted without implementation and transaction costs
- An undisclosed downstream partner delivering the actual funds
- No references from trials of comparable size and geography
The last carries the most weight. Ask for a reference running your protocol type in your countries.
Vendor Evaluation Scorecard
Score each vendor 1 to 5 on every criterion, multiply by the weighting, and compare totals.
| Evaluation criterion | Weighting |
| Site and participant workflow fit | 15% |
| Global coverage | 15% |
| Automation | 10% |
| Integrations and API | 10% |
| Participant experience | 10% |
| Site experience | 10% |
| Compliance, tax, and recipient onboarding | 10% |
| Reporting and reconciliation | 5% |
| Service and support | 5% |
| Total cost | 10% |
The scorecard makes trade-offs visible that are easy to miss during a demo.
Before You Sign the Contract
Product evaluation and procurement are separate exercises. Settle these during negotiation:
- Implementation. Onboarding responsibilities, data migration, integration build, validation scope, and country activation timelines. Coverage on a map and in production differ.
- SLAs. Payment processing times, platform uptime, support response, and incident handling, each with a remedy attached. An SLA without a remedy is a target.
- Data. Who owns the payment data, how it exports, retention period, and migration support at termination.
- Commercial terms. Minimum commitments, price increase caps, FX markup, and change-order pricing. Change orders are where quoted savings disappear.
- Exit terms. Remaining card balances, open site liabilities, historical reports, and transition assistance. Negotiate at signature, while the vendor still wants the deal.
Choose for the Workflow, Not the Vendor Logo
A polished site-payment platform can still leave participants with poor payout options. A strong participant-payment system can still rely on fund-delivery infrastructure you never evaluated. A global coverage claim means little if the method your participant needs is unavailable in their market.
Follow the money from the moment a payment is triggered to the moment it reaches the person who earned it, and confirm who owns every step, exception, and handoff. Running the same representative study through each vendor makes those handoffs visible before you sign.
If participant payout delivery is one of the gaps your evaluation exposes, see how PayQuicker orchestrates global clinical trial payouts at scale across countries, currencies, and payment methods.
FAQs
How Do Site Payment and Participant Payment Software Differ?
Site payment software calculates payments from clinical trial agreement schedules and study data, generates invoices, tracks holdbacks and accruals, and handles amendments. Participant payment software delivers stipends and expense reimbursement to individuals through multiple payment methods and manages tax documentation for each participant. Triggers and compliance obligations differ, so vendor capabilities rarely cover both equally.
How Do Clinical Trials Pay Participants?
Methods include reloadable prepaid cards, virtual cards, direct bank transfer, ACH, digital wallets, checks, gift cards, and local methods. Stipends usually pay per completed visit. Reimbursements cover documented travel, mileage, meals, and lodging. For tax years beginning after 2025, the IRS threshold for reporting these payments on an information return is $2,000, raised from $600. Compensation below that threshold can still be taxable to the recipient, and many institutions apply their own lower documentation thresholds.
How Do Sponsors Pay Clinical Trial Sites?
Sponsors pay against the negotiated clinical trial agreement. Payments trigger on completed visits recorded in the EDC, on milestones such as first patient enrolled or database lock, on startup fees, and on submitted invoices for pass-through costs. Many agreements hold back a percentage until closeout. The Society for Clinical Research Sites advocates monthly cycles for site financial stability.
